View Older Stories View More Recent Stories

Dec 7, 2020 10:15AM Eisai Presents Long-Term Seizure Freedom And Real-World Data Related To Anti-Epileptic Drug FYCOMPA® At The AES 2020 Annual Meeting
Dec 1, 2020 12:21PM Eisai To Present New Seizure Freedom And Real-World Clinical Practice Data Evaluating FYCOMPA® Across Diverse Patient Types At Upcoming AES 2020 Annual Meeting
Nov 20, 2020 06:00PM Eisai Announces New Investigational Data from Study 211 Evaluating the Starting Dose of LENVIMA® (lenvatinib) in Differentiated Thyroid Cancer at ESMO Asia 2020
Nov 19, 2020 09:10PM Eisai to Present New Investigational Data on LENVIMA® (lenvatinib) in Thyroid Cancer and Osteosarcoma at ESMO Asia 2020
Nov 7, 2020 07:00AM Eisai Announces New Investigational Data Evaluating TKI-mTOR Inhibitor Regimen LENVIMA® (lenvatinib) Plus Everolimus in Advanced Renal Cell Carcinoma (RCC) at IKCS 2020
Nov 5, 2020 07:00PM Eisai Announces Investigational Data Highlighting LENVIMA® (lenvatinib) Based Combination Therapy in Patients With Renal Cell Carcinoma at IKCS 2020
Nov 2, 2020 12:02PM Eisai to Present Latest Alzheimer's Disease Pipeline Research at Digital CTAD 2020, Including BAN2401, Anti-Microtubule Binding Region Tau Antibody, and Lemborexant Data
Sep 30, 2020 09:02AM Eisai Initiates Phase 3 MOMENTUM 1 Clinical Trial (Study 304) of Lorcaserin in Dravet Syndrome
Sep 10, 2020 07:30PM Eisai to Present New Data Highlighting KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and Eribulin Platform at ESMO 2020
Aug 28, 2020 11:31AM Eisai Presents New Analyses from Phase 3 Studies of DAYVIGO™ (lemborexant) CIV for the Treatment of Insomnia in Adult Patients at Virtual SLEEP 2020
Aug 24, 2020 08:10AM Eisai to Present Latest Insomnia Research, Including Data on New Treatment DAYVIGO™ (lemborexant) CIV, at the SLEEP 2020 Virtual Conference
Aug 11, 2020 09:05AM Eisai Pharmaceuticals to Make the ON3 Next-Generation Life-Science and Lifestyle Campus its U.S. Headquarters
Aug 11, 2020 08:08AM Eisai Announces Topline Results from Study 211 Supporting 24 mg as the Appropriate Starting Dose for LENVIMA® (lenvatinib) in Patients with Differentiated Thyroid Cancer
Jul 24, 2020 08:46AM Eisai Alzheimer's Disease Pipeline Research to be Presented at Virtual AAIC 2020, Including BAN2401 and Lemborexant Data and a Biomarker Symposium
Jun 1, 2020 08:05AM Eisai Announces U.S. Availability of DAYVIGO® (lemborexant) CIV, a New Treatment Option for Adults With Insomnia
May 29, 2020 08:35AM Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN® (eribulin mesylate) plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Triple-Negative Breast Cancer a
May 13, 2020 07:44PM Eisai to Present Latest Data from Oncology Pipeline at ASCO 2020, including KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and HALAVEN® (eribulin mesylate)
Mar 19, 2020 02:45PM Positive Results from Registrational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) in Advanced Endometrial Carcinoma Published in the Journal of Clinical Oncology
Feb 15, 2020 10:00AM Eisai Announces Latest Data for LENVIMA® (lenvatinib) in Combination with Everolimus for Advanced Non-Clear Cell Renal Cell Carcinoma
Feb 10, 2020 06:48PM Eisai to Present Latest on LENVIMA® (lenvatinib) at the 2020 Genitourinary Cancers Symposium
Feb 10, 2020 08:35AM METAvivor and Presenting Sponsor Eisai Inc. Team Up with AnaOno Intimates to Fearlessly Unite all Those Affected by Breast Cancer and Shine a Spotlight on Metastatic Breast Cancer during New York Fash
Feb 3, 2020 07:58AM Eisai Inc. Expands Leadership Team in the US with the Appointment of Two Key Leaders
Jan 21, 2020 05:27PM Eisai to Present Latest Data on LENVIMA® (lenvatinib) at the 2020 Gastrointestinal Cancers Symposium
Dec 27, 2019 11:13AM Pivotal Phase 3 Study of DAYVIGO™ (lemborexant) for the Treatment of Insomnia Disorder Published in JAMA Network Open
Dec 23, 2019 08:05AM U.S. FDA Approves Eisai's DAYVIGO™ (lemborexant) for the Treatment of Insomnia in Adult Patients
Dec 10, 2019 08:35AM Eisai Presents New Analyses of Potential Blood-Based Alzheimer's Diagnostic Test and Lemborexant as Potential Sleep-Wake Disorder Therapy
Dec 10, 2019 08:08AM Eisai to Present New Data on HALAVEN® (eribulin mesylate) Injection at 42nd Annual San Antonio Breast Cancer Symposium
Dec 9, 2019 10:06AM Lower Hospitalization Rates Seen Among Epilepsy Patients Treated with FYCOMPA® and Select Anti-Epileptic Drug (AED) Combinations
Dec 9, 2019 08:06AM Eisai Presents New Seizure Freedom and Adherence Data Related to Anti-Epileptic Drug FYCOMPA® at the 2019 American Epilepsy Society Annual Meeting
Dec 5, 2019 08:35AM Beneath the Breast Campaign from Eisai and METAvivor Supports Relationship Challenges Commonly Faced by People Living with Metastatic Breast Cancer and their Loved Ones
Dec 2, 2019 10:18AM Eisai and Biogen's Joint Investigational Asset BAN2401 Data to be Presented at Clinical Trials on Alzheimer's Disease Conference
Nov 25, 2019 08:06AM Eisai to Present Convulsive Seizure Freedom Data Evaluating FYCOMPA® in Newly Diagnosed Partial Onset Patients at Upcoming American Epilepsy Society Annual Meeting
Nov 12, 2019 08:35AM Eisai Launches First Amazon Alexa Skill Designed to Engage with Those Impacted by Lennox-Gastaut Syndrome - a Rare and Severe Form of Childhood-Onset Epilepsy
Sep 27, 2019 01:24PM Three New Analyses of Data Expand Understanding of the Potential Role for Investigational Agent Lemborexant in Insomnia and Irregular Sleep-Wake Rhythm Disorder
Sep 24, 2019 08:37AM New Findings Presented at World Sleep Congress Reveal Perceptions of "Having a Good Day" Determined by the Previous Night's Sleep
Sep 24, 2019 08:08AM Eisai Announces Data Presentations on KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and HALAVEN® (eribulin) at ESMO 2019
Sep 19, 2019 12:35PM Eisai to Present New 12-month Safety & Effectiveness Data from Phase 3 Lemborexant SUNRISE 2 Study and New Patient and Cohabitant Insights about Insomnia and Toll on Next-Day Functioning at World
Sep 13, 2019 08:01AM Eisai And Biogen (BIIB) to Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
Sep 13, 2019 08:00AM Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
Aug 26, 2019 07:55AM Priya Chaturvedi, Ph.D., Appointed Vice President of Global Clinical Quality Assurance at Eisai Inc.
Jun 25, 2019 08:00AM Eisai Presents Data To Assess Seizure Freedom With FYCOMPA® Monotherapy In Newly Diagnosed Or Untreated Patients With Partial Onset Seizures
Jun 13, 2019 08:05AM Eisai To Present FYCOMPA® Seizure FREEDOM Data In New Onset Patients And Pediatric Data At The 33rd International Epilepsy Congress
Jun 4, 2019 08:00AM Patrick Coyle Appointed Vice President and Chief Financial Officer of Eisai Inc.
May 16, 2019 12:45PM Eisai Announces Data Presentations on Oncology Pipeline, including LENVIMA® (lenvatinib) plus KEYTRUDA® (pembrolizumab) Investigational Combination Therapy at ASCO 2019
May 10, 2019 08:40AM Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer's Disease
May 9, 2019 01:17PM Lower Hospitalization Rates In Epilepsy Patients Treated With Adjunctive FYCOMPA® (perampanel) CIII
Mar 29, 2019 08:08AM Eisai Announces Presentations of Latest Research on Oncology Pipeline at the 110th American Association for Cancer Research (AACR) Annual Meeting
Feb 25, 2019 08:01AM FDA Accepts Eisai's Supplemental New Drug Application (sNDA) to Update the Labeling for Anti-Obesity Agent BELVIQ® (lorcaserin HCl)
Feb 19, 2019 10:05AM Eisai and Empatica Enter an Agreement to Co-Promote the Embrace2 Device for People Living With Epilepsy in the U.S.
Feb 11, 2019 08:35AM METAvivor and Presenting Sponsor Eisai Inc. Join Forces with AnaOno Intimates to Bring to Life the #ThisIsMBC Elements Campaign through Fashion
View More Recent Stories View Older Stories